Jan 10, 2014
Increased myelotoxicity of idarubicin: is there a pharmacological...
Cancer chemotherapy and pharmacology , Vol. 53, No. 1. , pp. 61-67, doi:10.1007/s00280-003-0700-2 Clinical trials evaluating idarubicin in acute myeloid leukemia, multiple myeloma and non-Hodgkin's lymphoma have provided some evidence for an increased myelotoxicity of IDA compared to other anthracyclines.
New Leukemia Study Findings Have Been Reported by Researchers at...
Editor at Cancer Gene Therapy Week -- Current study results on Oncology have been published.
Structural studies of several clinically important oncology drugs in complex with human serum albumin
Serum albumin is a major pharmacokinetic effector of drugs. To gain further insight into albumin binding chemistry, the crystal structures of six oncology agents were determined in complex with human serum albumin at resolutions of 2.8 to 2.0 A: camptothecin, 9-amino-camptothecin, etoposide, teniposide, bicalutamide and idarubicin.